Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 2
1983 1
1987 1
1988 1
1990 3
1991 1
1992 2
1994 3
1995 2
1996 2
1997 2
1998 4
2001 5
2002 12
2003 11
2004 7
2005 4
2006 5
2007 5
2008 5
2009 6
2010 1
2011 1
2012 5
2013 9
2014 7
2015 7
2016 7
2017 3
2018 8
2019 10
2020 15
2021 16
2022 14
2023 15
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Among authors: eren n. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J; NefIgArd trial investigators. Lafayette R, et al. Among authors: eren n. Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. Lancet. 2023. PMID: 37591292 Clinical Trial.
Primary pericardial mesothelioma.
Eren NT, Akar AR. Eren NT, et al. Curr Treat Options Oncol. 2002 Oct;3(5):369-73. doi: 10.1007/s11864-002-0002-7. Curr Treat Options Oncol. 2002. PMID: 12194802 Review.
Thirst intensity survey in ADPKD patients.
Gocay Bek SG, Yıldız N, Islam M, Ergul M, Sarıoglu I, Guven Taymez D, Eren N, Uslu H, Tosun M, Dervisoglu E, Kalender B, Balcı S, Waldreus N. Gocay Bek SG, et al. Among authors: eren n. Clin Exp Nephrol. 2023 Oct;27(10):819-827. doi: 10.1007/s10157-023-02373-7. Epub 2023 Jun 23. Clin Exp Nephrol. 2023. PMID: 37351680
Dasatinib-induced immune mediated-thrombotic thrombocytopenic purpura.
Demirsoy ET, Mehtap O, Atesoglu EB, Tarkun P, Eren N, Gedük A, Hacihanefioglu A. Demirsoy ET, et al. Among authors: eren n. Transfus Apher Sci. 2018 Apr;57(2):222-224. doi: 10.1016/j.transci.2018.02.003. Epub 2018 Feb 9. Transfus Apher Sci. 2018. PMID: 29475747
Smartphone-based gait assessment for multiple sclerosis.
Regev K, Eren N, Yekutieli Z, Karlinski K, Massri A, Vigiser I, Kolb H, Piura Y, Karni A. Regev K, et al. Among authors: eren n. Mult Scler Relat Disord. 2024 Feb;82:105394. doi: 10.1016/j.msard.2023.105394. Epub 2023 Dec 20. Mult Scler Relat Disord. 2024. PMID: 38141562
Correction to: Thirst intensity survey in ADPKD patients.
Bek SG, Yıldız N, Islam M, Ergul M, Sarıoglu I, Guven Taymez D, Eren N, Uslu H, Tosun M, Dervisoglu E, Kalender B, Balcı S, Waldreus N. Bek SG, et al. Among authors: eren n. Clin Exp Nephrol. 2023 Oct;27(10):828. doi: 10.1007/s10157-023-02375-5. Clin Exp Nephrol. 2023. PMID: 37428290 No abstract available.
Traumatic oesophageal perforation.
Inci I, Ozcelik C, Nizam O, Balci AE, Eren N, Ozgen G. Inci I, et al. Among authors: eren n. Scand Cardiovasc J. 1997;31(2):97-100. doi: 10.3109/14017439709058076. Scand Cardiovasc J. 1997. PMID: 9211597
181 results